• Laboratorios Farmacéuticos ROVI posted Q1 2026 operating revenue of €152.5 million, down 1.5% year over year.
• EBITDA fell to €23 million from €30.3 million, while net profit dropped to €18.1 million from €20.3 million.
• Gross margin widened 3.8 percentage points to 62.3%, supported by CDTI R&D aid for the LAISOLID project, higher Okedi® contribution, lower LMWH raw material prices, and higher CDMO sales.
• CDMO revenue rose 5% to €37.4 million, while specialty pharmaceutical business slipped 3% on a 12% decline in the heparin franchise despite Okedi® sales growth of 37%.
• ROVI closed acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona in April, while keeping 2026 guidance for operating revenue growth of a low- to mid-single-digit percentage vs 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorios Farmacéuticos ROVI SA published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.